Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2021 Filed Jan 26, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-005226 · doc4.xml · derivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 9,476 | $67.19 | $636,692.44 |
DisclosureSEC source: 0001209191-21-005226 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.84 to 67.48, inclusive. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 5,524 | $66.23 | $365,854.52 |
DisclosureSEC source: 0001209191-21-005226 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,476 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.82 to 66.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-005226 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-004972 · doc4.xml · derivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 45 | $67.63 | $3,043.35 |
DisclosureSEC source: 0001209191-21-004972 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 8,511 | $66.87 | $569,130.57 |
DisclosureSEC source: 0001209191-21-004972 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.62 to 67.27, inclusive. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 6,444 | $66.15 | $426,270.60 |
DisclosureSEC source: 0001209191-21-004972 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,556 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.52 to 66.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-004972 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 21, 2021 Filed Jan 26, 2021 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 23,370 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-005233 · doc4.xml · derivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,330 Underlying: Common Stock · 23,370 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. F6 · balance_after: The number of beneficially owned stock options has been increased by 100,000 shares to reflect an inadvertently misattributed option exercise reported on the insider's Form 4, filed January 21, 2021 and subsequently amended on January 25, 2021. Read SEC document |
| January 21, 2021 Filed Jan 26, 2021 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 2,100 | $67.59 | $141,939.00 |
DisclosureSEC source: 0001209191-21-005233 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $67.45 to 67.78, inclusive. Read SEC document |
| January 21, 2021 Filed Jan 26, 2021 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 17,329 | $66.90 | $1,159,310.10 |
DisclosureSEC source: 0001209191-21-005233 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,779 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.55 to 67.44, inclusive. Read SEC document |
| January 21, 2021 Filed Jan 26, 2021 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,941 | $66.06 | $260,342.46 |
DisclosureSEC source: 0001209191-21-005233 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,108 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.51 to 66.45, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 26, 2021 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 23,370 | $6.32 | $147,698.40 |
DisclosureSEC source: 0001209191-21-005233 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F9 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 6,370 | $68.34 | $435,325.80 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · nonDerivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $68.25 to 68.73, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 4,264 | $67.58 | $288,161.12 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,370 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $67.09 to 68.02, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 4,366 | $66.49 | $290,295.34 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,634 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.05 to 67.00, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 02:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-004771 · doc4.xml · derivative · entry 12 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,700 Underlying: Common Stock · 50,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 02:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 4,661 | $68.20 | $317,880.20 |
DisclosureSEC source: 0001209191-21-004771 · doc4.xml · nonDerivative · entry 10 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F9 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $68.07 to 68.48, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 02:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 24,945 | $67.39 | $1,681,043.55 |
DisclosureSEC source: 0001209191-21-004771 · doc4.xml · nonDerivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,340 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $67.07 to 68.06, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 02:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 20,394 | $66.84 | $1,363,134.96 |
DisclosureSEC source: 0001209191-21-004771 · doc4.xml · nonDerivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,285 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.07 to 67.06, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 02:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 50,000 | $6.32 | $316,000.00 |
DisclosureSEC source: 0001209191-21-004771 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 00:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-004973 · doc4.xml · derivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 50,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 00:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 5,012 | $68.33 | $342,469.96 |
DisclosureSEC source: 0001209191-21-004973 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $68.025 to $69.00, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 00:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 33,938 | $67.35 | $2,285,724.30 |
DisclosureSEC source: 0001209191-21-004973 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,012 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $67.02 to 68.01, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 00:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 11,050 | $66.82 | $738,361.00 |
DisclosureSEC source: 0001209191-21-004973 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,950 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.04 to 67.01, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 00:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 50,000 | $6.32 | $316,000.00 |
DisclosureSEC source: 0001209191-21-004973 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| January 20, 2021 Filed Jan 26, 2021 00:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-005222 · doc4a.xml · derivative · entry 12 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 50,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F10 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 20, 2021 Filed Jan 26, 2021 00:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 4,661 | $68.20 | $317,880.20 |
DisclosureSEC source: 0001209191-21-005222 · doc4a.xml · nonDerivative · entry 10 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F9 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $68.07 to 68.48, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 26, 2021 00:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 24,945 | $67.39 | $1,681,043.55 |
DisclosureSEC source: 0001209191-21-005222 · doc4a.xml · nonDerivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,340 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $67.07 to 68.06, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 26, 2021 00:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 20,394 | $66.84 | $1,363,134.96 |
DisclosureSEC source: 0001209191-21-005222 · doc4a.xml · nonDerivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,285 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.07 to 67.06, inclusive. Read SEC document |
| January 20, 2021 Filed Jan 26, 2021 00:00 UTC Amendment |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 50,000 | $6.55 | $327,500.00 |
DisclosureSEC source: 0001209191-21-005222 · doc4a.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 417 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001209191-21-004523 · doc4.xml · derivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 417 shares Expires 2027-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 417 | $69.00 | $28,773.00 |
DisclosureSEC source: 0001209191-21-004523 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 00:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 417 | $6.27 | $2,614.59 |
DisclosureSEC source: 0001209191-21-004523 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 100 | $71.14 | $7,114.00 |
DisclosureSEC source: 0001209191-21-004773 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,769,780 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 8,300 | $70.42 | $584,486.00 |
DisclosureSEC source: 0001209191-21-004773 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,769,880 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $70.03 to 71.02, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F9 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 200 | $71.23 | $14,246.00 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $71.20 to 71.25, inclusive. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 4,822 | $70.51 | $339,999.22 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $70.07 to 71.00, inclusive. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 7,415 | $69.54 | $515,639.10 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,022 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $69.06 to 70.00, inclusive. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 2,563 | $68.72 | $176,129.36 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,437 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $68.03 to 69.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-004770 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-21-004769 · doc4.xml · derivative · entry 8 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 23,000 shares Expires 2025-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-21-004769 · doc4.xml · derivative · entry 7 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2023-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
SaleCommon Stock | 25,000 | $69.00 | $1,725,000.00 |
DisclosureSEC source: 0001209191-21-004769 · doc4.xml · nonDerivative · entry 3 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
Exercise / conversionCommon Stock | 23,000 | $4.07 | $93,610.00 |
DisclosureSEC source: 0001209191-21-004769 · doc4.xml · nonDerivative · entry 2 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:00 UTC |
HILL NANCY LOUISEEVP, Operations & Program Mana
|
Exercise / conversionCommon Stock | 2,000 | $0.84 | $1,680.00 |
DisclosureSEC source: 0001209191-21-004769 · doc4.xml · nonDerivative · entry 1 HILL NANCY LOUISE · CIK 0001780790 · EVP, Operations & Program Mana 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.